A Phase 1, Open-Label, 10 Day Safety Study

Phase 1 Completed 72 enrolled Merck & Co., Inc.

NaSingle-groupOpen-labelOther

Summary

This is a Phase 1 open-label study in healthy volunteers who will receive oral 200 mg TR 701 FA once daily for 10 days and will include ophthalmologic and neurologic assessments.

Timeline

Start: 2012-05-17
Primary completion: 2012-08-24
Completion: 2012-08-24

Publications

Results Fang E, Munoz KA, Prokocimer P. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers. Am J Ther. 2017 Mar/Apr;24(2):e227-e233. doi: 10.1097/MJT.0000000000000534.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tedizolid	Small molecule	200 mg	Oral

Indications

No indication recorded.